Table 3.
Retention of Patients at 6, 12, 18, 24 and 36 months after initiation of antiretroviral therapy in sub-Saharan Africa
| Percentage of patients retained at month | ||||||
|---|---|---|---|---|---|---|
| Study code | 6 | 12 | 18 | 24 | 36 | Notes |
| Botswana 1 | – | 77.8% | – | – | – | 12 month value is at a median of 10.1 months |
| Botswana 2 | – | 73.8% | – | – | 63.9% | Values estimated from KM estimates of LTFU and death |
| Cameroon 1 | – | 65.0% | – | – | – | Values estimated from KM curves counting LTFU as an event |
| Congo 1 | 94.0% | 89.0% | – | – | – | Survival reported as combined LTFU and death |
| Cote d’Ivoire 1 | – | – | 64.0% | – | – | 18 month estimate of death and LTFU summed |
| DRC 1 | – | 86.7% | – | – | – | |
| Ethiopia 1 | 72.3% | – | – | – | – | |
| Ghana 1 | 87.0% | 81.0% | 77.0% | 68.0% | – | |
| Ghana 2 | – | 82.5% | 74.7% | – | 68.1% | Estimated based on number of patients reporting for follow-up visits; no deaths reported |
| Kenya 1 | 83.0% | 74.0% | – | 65.0% | – | Estimated using survival analysis. No deaths reported |
| Malawi 1 | – | 77.0% | – | 70.0% | 68.0% | Includes stopping ART as attrition |
| Mozambique 1 | 86.0% | 79.0% | – | – | – | |
| Multiple 1 | – | 91.3% | – | – | – | Attributed total death and LTFU to 12 months |
| Multiple 2 | – | – | 86.7% | – | – | 18 months value based on mean 15 months follow-up |
| Nigeria 1 | – | – | 84.5% | – | – | 18 months value based on mean 15 months follow-up |
| Rwanda 1 | 94.0% | 93.0% | 91.0% | 89.0% | – | |
| Rwanda 2 | 93.0% | 91.0% | – | – | – | Excluded transfers and stopping ART from reported attrition |
| SA 1 | 89.1% | 84.9% | 81.3% | 80.9% | 77.0% | Estimates are from nested cohorts |
| SA 2 | 76.0% | 71.0% | 70.0% | 68.0% | 64.0% | Estimated from KM curves; includes patients transferred as attrition |
| SA 3 | 83.5% | – | – | – | – | |
| SA 4a | – | – | – | 79.6% | – | |
| SA 4b | – | – | – | – | 87.0% | |
| SA 5 | 87.4% | 84.1% | – | 77.6% | 72.8% | Includes patients transferred as attrition |
| SA 6 | – | – | – | – | 74.3% | Rate from KM estimates. Weighted average of pregnant and non-pregnant subjects. |
| SA 7 | – | – | – | 83.6% | – | |
| SA 8 | – | – | – | 86.8% | – | Study compared EFV and NVP; rates shown are for combined cohort. |
| SA 9 | 76.7% | – | – | – | – | 6 month estimate at 8 months |
| SA 10a | – | 74.0% | – | – | – | |
| SA 10b | – | 55.0% | – | – | – | |
| SA 10c | – | 72.0% | – | – | – | |
| SA 10d | – | 87.0% | – | – | – | |
| Tanzania 1 | – | 85.4% | – | – | – | |
| Tanzania 2 | – | 60.6% | – | – | – | 12 month estimate at 11 months |
| Uganda 1a | – | 75.7% | – | – | – | Data are from retrospective cohort analysis; excluded transfers and stopping ART from reported attrition |
| Uganda 1b | – | – | – | 68.2% | – | Data is from retrospective cohort analysis; excluded transfers and stopping ART from reported attrition |
| Uganda 2 | 85.0% | 77.0% | – | 73.0% | – | Includes those who stopped treatment |
| Uganda 3 | – | 76.0% | – | 71.0% | – | |
| Uganda 4 | 91.0% | – | – | – | – | 6 month estimate at 8.3 months |
| Zambia 1 | – | 73.2% | – | – | – | |
| Simple averages | 85.6% | 78.3% | 78.6% | 75.4% | 71.9% | |
KM, Kaplan-Meier.